About Us
World-recognized R&D company for creating market value through innovative new drugs


Huntaek Kim Ph.D., MBA
He is a top-class leader in the synthetic/ biopharmaceutical area who has successfully led a number of development projects, some of which resulted in global license-out deals.
  • 2014, Excellent Researcher in New Drug Development, Ministry of Health and Welfare Award
  • 2013, South Korea's Top 10 New Technology
  • 2009, R&D of Korea's first gene recombination protein hemophilia (NBP601) treatment and global
  • R&D and market launch of Korea's first synthetic new anti-cancer drug Sunfla, nature-based new drug Joins, and MVIXX
  • Application/registration of 67 domestic/international patents related to synthetic and bio-new drugs
  • VP (Center Head), Innovative R&D Center, SK Chemicals
  • VP (Chief), New Drug Discovery Lab, SK Chemicals
  • In2gen research lab (Bio spin-off from SK Chemicals)
  • Visiting Researcher, Otsuka Pharma Life Science Research Center
  • Sunkyung Industry Life-science Research Center
  • Ph.D., Texas A&M University, US (molecular pathophysiology)
  • MBA, University of Southern California, US
  • MS/BS, Veterinary Dept. Seoul Nat'l Univ., Republic of Korea